GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase Ib, dose-escalation study designed to assess the
safety, tolerability, and pharmacokinetics of oral GDC-0980 administered in combination with
capecitabine and with mFOLFOX6 chemotherapy with bevacizumab added on at Cycle 5 in patients
with advanced or metastatic solid tumors.